Anika Therapeutics, Inc. beat EPS estimates 67% of the time across 3 reported quarters (2 beats, 1 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.19 | $0.30 | +257.9% | Beat |
| Q12026 FY2026 | $-0.21 | $-0.24 | -14.3% | Miss |
| Q42025 FY2025 | $-0.19 | $0.13 | +168.4% | Beat |
Back to ANIK overview · ANIK holders · ANIK KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.